Gossamer Bio (GOSS)
NASDAQ:GOSS
Want to see GOSS full AI Analyst Report?
GOSS Stock Chart & Stats
$0.45
-$0.10(-9.01%)
At close: 4:00 PM EST
$0.45
-$0.10(-9.01%)
Day’s Range― - ―
52-Week Range$0.16 - $3.87
Previous CloseN/A
Volume602.63K
Average Volume (3M)8.99M
Market Cap
$49.31M
Enterprise Value$211.21M
Total Cash (Recent Filing)$99.22M
Total Debt (Recent Filing)$202.93M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Aug 11, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding234,696,270
10 Day Avg. Volume16,638,468
30 Day Avg. Volume8,985,629
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-5.77
Price to Sales (P/S)14.62
P/FCF Ratio-4.13
Enterprise Value/Market Cap4.28
Enterprise Value/Revenue3.80
Enterprise Value/Gross Profit3.82
Enterprise Value/Ebitda-1.24
Forecast
1Y Price Target
$5.32Price Target Upside1082.22% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$25.83M
Bulls Say, Bears Say
Bulls Say
High‑risk Subgroup EfficacyClinically meaningful improvements observed in a predefined higher‑risk patient subgroup suggest a feasible path to demonstrate benefit in a targeted population and inform a focused regulatory or labeling strategy.
Mechanistic DifferentiationSeralutinib's design to target vascular remodeling, inflammation and fibrosis rather than only providing vasodilation supports claims of disease‑modifying potential and bolsters confidence if durability signals persist.
Regulatory StrategyA planned Type C meeting with the FDA to discuss a two‑trial NDA creates a potential regulatory catalyst by seeking clarity on whether a two‑study submission will satisfy approval requirements.
Bears Say
Enrollment And Development MomentumPaused enrollment in the ongoing Phase 3 study disrupts development momentum and raises concerns about the ability to complete confirmatory programs on schedule.
Missed Primary EndpointPROSERA failing to meet its primary endpoint introduces major uncertainty about approval prospects and weakens the case for relying on a single registrational trial.
Trial Dataset Quality And Placebo VariabilityStructural issues in the trial dataset and unexpected placebo performance increase the risk that regulators will question the robustness of the evidence and decline a two‑study filing approach.
Gossamer Bio News
GOSS FAQ
What was Gossamer Bio’s price range in the past 12 months?
Gossamer Bio lowest stock price was $0.16 and its highest was $3.87 in the past 12 months.
What is Gossamer Bio’s market cap?
Gossamer Bio’s market cap is $49.31M.
When is Gossamer Bio’s upcoming earnings report date?
Gossamer Bio’s upcoming earnings report date is Aug 11, 2026 which is in 76 days.
How were Gossamer Bio’s earnings last quarter?
Gossamer Bio released its earnings results on May 18, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.166 by -$0.034.
Is Gossamer Bio overvalued?
According to Wall Street analysts Gossamer Bio’s price is currently Undervalued.
Does Gossamer Bio pay dividends?
Gossamer Bio does not currently pay dividends.
What is Gossamer Bio’s EPS estimate?
Gossamer Bio’s EPS estimate is -0.12.
How many shares outstanding does Gossamer Bio have?
Gossamer Bio has 234,696,270 shares outstanding.
What happened to Gossamer Bio’s price movement after its last earnings report?
Gossamer Bio reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.166. Following the earnings report the stock price went down -43.529%.
Which hedge fund is a major shareholder of Gossamer Bio?
Currently, no hedge funds are holding shares in GOSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gossamer Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.32 (1082.22% Upside)
$5.32 (1082.22% Upside)
Blogger Sentiment
Bullish
GOSS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 9.7%
Last 30 Days ▼ 9.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.89%
12-Months-Change
Fundamentals
Return on Equity
174.85%
Trailing 12-Months
Asset Growth
-54.06%
Trailing 12-Months
Company Description
Gossamer Bio
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
GOSS Company Deck
GOSS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but constructive picture: clinically meaningful efficacy signals (including a traditional statistical threshold for 6MWD), supportive mechanistic CT FRI data across multiple lung compartments with clinical correlations, and decisive capital actions (debt reduction plan and cost containment) to preserve runway and focus on an NDA path. Counterbalancing these positives were key execution risks — the primary endpoint did not meet the prespecified alpha, a substantial workforce reduction was implemented, cash runway is short ($99M to Q1 2027), and the debt exchange depends on high noteholder participation and involves tradeoffs. Overall, the tone is cautious and pragmatic, emphasizing strengthened conviction in the program but acknowledging material near-term financial and regulatory risks.View all GOSS earnings summariesGOSS Stock 12 Month Forecast
Average Price Target
$5.32
▲(1082.22% Upside)
Technical Analysis
Ownership Overview
3.88% Insiders
7.67% Mutual Funds
25.80% Other Institutional Investors
51.40% Public Companies and Individual Investors